|AI Robots Name||P/L||Entry Price, $||Profit, $/%|
|AI Robots Name||P/L||Entry Price, $||Profit, $/%|
The Aroon Indicator for ALKS entered a downward trend on March 23, 2023. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 155 similar instances where the Aroon Indicator formed such a pattern. In 118 of the 155 cases the stock moved lower. This puts the odds of a downward move at 76%.
The Momentum Indicator moved below the 0 level on March 15, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on ALKS as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ALKS moved below its 50-day moving average on March 07, 2023 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ALKS crossed bearishly below the 50-day moving average on March 08, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALKS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Indicator entered the oversold zone -- be on the watch for ALKS's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALKS advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
ALKS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALKS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.055) is normal, around the industry mean (6.765). P/E Ratio (0.000) is within average values for comparable stocks, (48.055). ALKS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.964). ALKS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.026). P/S Ratio (3.788) is also within normal values, averaging (87.845).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALKS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of pharmaceutical products
|ETFs / NAME||Price $||Chg $||Chg %|
|iShares ESG Aware Moderate Allc ETF|
|First Trust Dev Mkts Ex-US AlphaDEX® ETF|
|WisdomTree US LargeCap Dividend ETF|
|Invesco S&P 500® Enhanced Value ETF|
|Global X Alternative Income ETF|
A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with DCPH. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then DCPH could also see price increases.
|DCPH - ALKS|
|NBIX - ALKS|
|SUPN - ALKS|
|DVAX - ALKS|
|ANIP - ALKS|